Kymera Therapeutics (KYMR) Financial Analysis & Valuation | Quarter Chart
Kymera Therapeutics (KYMR)
KYMRPrice: $109.32
Fair Value: 🔒
🔒score
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in ... more
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel ... more
Description
Shares
| Market Cap | $8.99B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Nello Mainolfi |
| IPO Date | 2020-08-21 | CAGR | — |
| Employees | 208 | Website | www.kymeratx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KYMR chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.51B | P/E Ratio | -30.97 |
| Forward P/E | -25.15 | PEG Ratio | — |
| P/S Ratio | 250.4 | P/B Ratio | 9.94 |
| P/CF Ratio | -62.98 | P/FCF Ratio | -52.83 |
| EPS | $-3.53 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -12.6% | Gross Margin | 1% |
| Operating Margin | -6.98% | Profit Margin | -6.12% |
| ROE | -0.25% | ROA | -0.19% |
| ROCE | -0.22% | Current Ratio | 10.81 |
| Quick Ratio | 10.81 | Cash Ratio | 2.3 |
| Debt/Equity | 0.05 | Interest Coverage | -1508.94 |
| Altman Z Score | 40.35 | Piotroski Score | 2 |